TB Infection
US Preventive Services Task Force Recommendations
Targeted Testing and Treatment
Risk Assessment
Testing and Treatment
US Preventive Services Task Force (USPSTF) Recommendations
- USPSTF: Final Recommendations on Screening for Latent Tuberculosis Infection (LTBI)
- NTCA and Stop TB USA: Press release
- CDC: LTBI web page with USPSTF recommendations resources
- Jonathon Mermin: “The End Game – Eliminating Tuberculosis In America” (Huffington Post)
Targeted Testing and Treatment
Risk Assessment
- California and California TB Controllers Association: California Tuberculosis Risk Assessment Tool (2016)
- Michigan: Latent TB Infection Risk Assessment Tool (2016)
Testing and Treatment
- NSTC: Testing and Treatment of Latent Tuberculosis Infection in the United States: A Clinical Guide for Health Care Providers and Public Health Programs (2025)
- NTCA Provider Guidance: Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI) (2018)
- California: Fact Sheet: 12-dose Isoniazid (INH)/Rifapentine Regimen for Latent TB Infection Treatment (2017)
- Minnesota: Treatment for Latent Tuberculosis (TB) Infection: Isoniazid and Rifapentine (INH-RPT): Information for Patients (2016, multiple languages)
- Oregon: 12-dose Isoniazid (INH)/Rifapentine Regimen (3HP) for Treatment of Latent TB Infection (LTBI) (2018)
